Innovent Biologics, Inc. announced that, five products (including new indications) of the company have been included in the updated National Reimbursement Drug List (2022 Version) ("NRDL"). This includes: two additional indications of PD-1 inhibitor TYVYT® (sintilimab injection) were included (negotiation list); olverembatinib was included for the first time (negotiation list); multiple additional indications of BYVASDA® (bevacizumab injection), HALPRYZA® (rituximab injection), and SULINNO® (adalimumab injection) were included (general list). The updated NRDL will officially take effect on March 1st, 2023.

This time, TYVYT® has been included in the NRDL for two additional indications including gastric cancer and esophageal cancer. TYVYT® is the first and the only PD-1 inhibitor for gastric cancer in the NRDL, as well as the only PD-1 inhibitor for the first-line treatment of five high-incidence cancer types in the NRDL. Olverembatinib, as an exclusive third generation BCR-ABL inhibitor, has been included in the NRDL for the first time, filling the gap in the treatment of chronic myeloid leukemia (CML) patients harboring the T315I mutation.

In addition, all the new indications of BYVASDA®, HALPRYZA® and SULINNO® have been included in the updated NRDL this year, expanding the reimbursement coverage and benefiting broader patient groups. TYVYT® (sintilimab injection): an innovative PD-1 inhibitor co-developed by Innovent and Eli Lilly and Company. Six indications of TYVYT® for the treatment of lung cancer, liver cancer, gastric cancer, esophageal cancer, Hodgkin's lymphoma, etc.

have been approved and included in the NRDL[1][i]. In particular, two additional indications of TYVYT® for the treatment of gastric cancer and the treatment of esophageal cancer have been included in the NRDL for the first time, further enhancing the accessibility of this novel immunotherapy to a wider group of cancer patients. TYVYT® is the first and the only PD-1 inhibitor for gastric cancer in the NRDL, as well as the only PD-1 inhibitor for the first-line treatment of five high-incidence cancer types (non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer) in the NRDL.

Olverembatinib: an innovative third generation BCR-ABL inhibitor co-commercialized by Innovent and Ascentage Pharma. Olverembatinib has been included in the NRDL for the first time for adult patients with T315I-mutant chronic-phase chronic myeloid leukemia (CML-CP) and accelerated-phase chronic myeloid leukemia (CML-AP).